Research programme: neurodegenerative disease therapeutics - American Life Science Pharmaceuticals
Latest Information Update: 07 Jul 2016
At a glance
- Originator American Life Science Pharmaceuticals
- Mechanism of Action Cysteine endopeptidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 07 Jul 2016 Early research in Neurodegenerative disorders in USA (unspecified route)